Abbott Signs Global Deal to License ALZpath pTau217 for Alinity Alzheimer’s Test
ABT•Abbott signed a global licensing agreement with ALZpath to incorporate ALZpath’s proprietary phosphorylated Tau 217 antibody into a blood-based in vitro diagnostic test for Alzheimer’s disease on its Alinity ci-series systems. The deal leverages Abbott’s extensive install base to enable scalable, early Alzheimer’s detection beyond costly PET and CSF methods.
1. Licensing Agreement Details
Abbott entered a global licensing agreement with ALZpath to integrate its proprietary phosphorylated Tau 217 (pTau217) antibody into a new blood-based in vitro diagnostic test for Alzheimer’s disease. The assay is designed for Abbott’s Alinity ci-series immunoassay systems, leveraging one of the largest installed bases worldwide to streamline deployment.
2. Technology and Validation
ALZpath’s pTau217 antibody is backed by over 200 peer-reviewed studies across 18 countries, demonstrating high accuracy and sensitivity in detecting Alzheimer’s pathology. Its clinical validation positions Abbott’s forthcoming assay to offer reliable early detection of disease biology through routine blood draws.
3. Market Impact and Outlook
By utilizing blood-based biomarkers instead of costly PET scans or invasive cerebrospinal fluid analysis, Abbott aims to expand access to early Alzheimer’s diagnosis and support monitoring of disease progression and treatment response. The partnership could bolster Abbott’s diagnostics portfolio and drive growth in its core immunoassay segment.
